Last updated: February 19, 2026
European Patent EP1853265, titled "Imidazoline derivatives," claims a class of compounds for treating conditions associated with alpha-2 adrenergic receptor antagonism. The patent, granted to Aventis Pharma Deutschland GmbH, protects imidazoline derivatives and their use in pharmaceuticals. The claims encompass compound structures, pharmaceutical compositions, and specific therapeutic applications. The patent landscape surrounding these compounds is characterized by a moderate number of generic competitors and active research from other pharmaceutical entities exploring similar targets.
What is the Core Innovation Protected by EP1853265?
The primary innovation protected by EP1853265 lies in a specific class of imidazoline derivatives. These compounds are structurally defined by a central imidazoline ring substituted with various functional groups designed to interact with alpha-2 adrenergic receptors. The patent specifies a general formula for these compounds and provides concrete examples of synthesized molecules.
The disclosed compounds are characterized by the following general structure:
- A substituted imidazoline ring.
- Specific substituents at defined positions on the imidazoline ring and attached aromatic or heteroaromatic groups.
The patent details a range of potential therapeutic uses for these compounds, primarily focused on modulating alpha-2 adrenergic receptor activity.
What is the Claimed Scope of EP1853265?
The claims of EP1853265 delineate the intellectual property protection granted. The patent contains several independent and dependent claims, covering different aspects of the invention.
Independent Claims:
- Claim 1: Protects a compound of Formula I or a pharmaceutically acceptable salt, solvate, or prodrug thereof. Formula I is defined by a specific structural framework, including a substituted imidazoline ring. The substituents are detailed in sub-clauses that allow for a broad range of variations.
- For example, the structure may include an aryl or heteroaryl group attached to the imidazoline ring, with various substituents on these rings, such as halogen, alkyl, alkoxy, nitro, and amino groups.
- The imidazoline ring itself is also subject to substitution, affecting its pharmacokinetic and pharmacodynamic properties.
- Claim 5: Claims a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient. This claim broadens protection to formulations containing the active compound.
- Claim 8: Claims the use of a compound according to Claim 1 for the manufacture of a medicament for treating a disease or condition associated with alpha-2 adrenergic receptor antagonism. The patent lists specific examples of such conditions.
Dependent Claims:
Dependent claims further refine the scope by narrowing the broad independent claims. These claims specify particular substituents, preferred compounds, or more specific therapeutic applications.
- Claims dependent on Claim 1 may specify particular ranges for alkyl chain lengths, specific types of heteroaryl groups, or particular positions for functional groups on the aryl/heteroaryl moieties.
- These dependent claims often recite specific compound numbers disclosed in the patent's examples.
Therapeutic Indications within the Claims:
The patent explicitly lists several therapeutic indications that fall within the scope of the claimed uses. These are conditions where modulation of alpha-2 adrenergic receptors is considered beneficial.
- Pain Management: Alpha-2 adrenergic agonists have shown analgesic properties, and EP1853265 claims compounds for treating pain, particularly neuropathic pain and chronic pain.
- Anxiety and Depression: Modulation of alpha-2 adrenergic receptors is implicated in mood regulation, and the patent suggests uses in treating anxiety disorders and depressive states.
- Cardiovascular Conditions: Alpha-2 adrenergic receptors play a role in blood pressure regulation. The patent claims potential use in managing hypertension.
- Opioid Withdrawal: Alpha-2 adrenergic agonists are used to manage symptoms of opioid withdrawal, and this application is covered.
- Attention Deficit Hyperactivity Disorder (ADHD): Compounds acting on adrenergic receptors are a basis for ADHD treatment, and this use is also claimed.
The breadth of Claim 1, combined with the specific examples and listed indications, provides a significant scope of protection for Aventis Pharma Deutschland GmbH.
What is the Patent Landscape for EP1853265?
The patent landscape surrounding EP1853265 involves other patent filings, generic competition, and ongoing research in the alpha-2 adrenergic receptor modulation space. Understanding this landscape is critical for assessing market entry and R&D strategy.
Key Players and Filing Trends:
The landscape is populated by:
- The Patent Holder (Aventis Pharma Deutschland GmbH/Sanofi): As the original applicant and subsequent assignee (Sanofi), Aventis (now Sanofi) holds the primary patent and potentially related follow-on patents or divisional applications.
- Generic Competitors: Once the patent expires or is successfully challenged, generic manufacturers will seek to enter the market. Their activity is typically observed through filings for regulatory approval and Abbreviated New Drug Applications (ANDAs) in markets like the US or similar pathways in Europe.
- Other Pharmaceutical Companies: Numerous companies are actively researching alpha-2 adrenergic receptor modulators for various indications. This is reflected in patent filings that may:
- Claim novel compounds within the same structural class but with distinct structural features not covered by EP1853265.
- Explore different therapeutic applications of alpha-2 modulators.
- Develop novel formulations or delivery systems for existing alpha-2 modulators.
- Target specific subtypes of alpha-2 receptors (e.g., alpha-2A, alpha-2B, alpha-2C) with greater selectivity.
Key Patent Families and Competitor Activity:
While a detailed analysis of every competing patent is extensive, general trends indicate several areas of activity:
- Selectivity: A significant trend in the field is the development of compounds with increased selectivity for specific alpha-2 receptor subtypes. This aims to improve efficacy and reduce side effects associated with non-selective alpha-2 agonists/antagonists. Companies like Merck, Pfizer, and smaller biotechs have active patent portfolios in this area.
- New Indications: Beyond the established uses, research explores alpha-2 modulators for conditions such as irritable bowel syndrome (IBS), glaucoma, and certain dermatological conditions. Patent filings in these areas suggest diversification of therapeutic targets.
- Formulation and Delivery: Innovation in drug delivery systems is also evident. Patents may cover extended-release formulations, topical applications, or novel routes of administration for alpha-2 modulators, aiming to improve patient compliance and therapeutic outcomes.
- Combination Therapies: Some patent filings explore the use of alpha-2 modulators in combination with other therapeutic agents to achieve synergistic effects or broaden the therapeutic window.
Challenges to Patent Validity and Enforcement:
The enforceability of EP1853265 can be challenged on several grounds:
- Novelty and Inventive Step: Competitors may argue that the claimed compounds or their therapeutic uses were already known or obvious based on prior art. This requires extensive prior art searches, including scientific literature, existing patents, and patent applications.
- Enablement and Sufficiency of Disclosure: It could be argued that the patent does not sufficiently describe how to make and use the claimed compounds, or that the claims are broader than what is adequately described.
- Lack of Specificity: In certain jurisdictions, overly broad claims that do not clearly define the invention can be narrowed or invalidated.
The patent landscape for alpha-2 adrenergic receptor modulators is dynamic, with continuous filings and developments. Companies seeking to operate in this therapeutic space must conduct thorough freedom-to-operate (FTO) analyses to ensure they do not infringe existing patents, including EP1853265 and its potential continuations or related filings.
What are the Key Dates and Status of EP1853265?
Understanding the timeline and current status of EP1853265 is crucial for strategic planning regarding market entry and patent expiry.
Key Dates:
- Filing Date: October 17, 2005
- Publication Date: May 9, 2007 (as EP 1853265 A1)
- Grant Date: October 17, 2012
- Expiry Date (Initial Term): October 17, 2025
Status:
- Granted: The patent has been granted by the European Patent Office (EPO).
- In Force: The patent is currently in force, subject to the payment of renewal fees in designated European Patent Convention (EPC) member states.
Implications of Expiry:
Upon expiry on October 17, 2025, the compounds and therapeutic uses claimed in EP1853265 will enter the public domain in countries where the patent has been validated and maintained. This will permit generic manufacturers to market equivalent products, provided they obtain necessary regulatory approvals and do not infringe any other valid patents, such as those covering specific polymorphs, formulations, or manufacturing processes not disclosed or claimed in EP1853265.
Potential for Extensions:
In certain jurisdictions, patent term extensions (PTE) or supplementary protection certificates (SPC) may be available for pharmaceutical patents to compensate for regulatory review periods. If Aventis Pharma Deutschland GmbH or its assignee has applied for and been granted such extensions in relevant European countries, the effective market exclusivity period for the claimed inventions could be extended beyond the initial expiry date. These extensions are country-specific and depend on national regulations and the timing of regulatory approvals for marketed products based on the patent.
What is the Commercial Relevance of EP1853265?
The commercial relevance of EP1853265 is tied to the therapeutic areas it covers and the market potential of alpha-2 adrenergic receptor modulators.
Therapeutic Areas and Market Size:
The patent covers a range of indications, each with significant market value:
- Pain Management: The global pain management market is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. The segment for neuropathic pain, specifically mentioned in the patent, is also growing rapidly.
- Anxiety and Depression: Mental health disorders represent a vast and expanding market. Alpha-2 modulators offer an alternative or adjunctive approach to existing treatments.
- ADHD: The market for ADHD medications is well-established and continues to grow, with unmet needs for improved efficacy and tolerability.
- Hypertension: While a mature market, there is ongoing demand for effective antihypertensive agents, especially those with novel mechanisms of action.
Competitive Landscape and Market Exclusivity:
The commercial value of EP1853265 is directly influenced by the competitive landscape. The patent provides market exclusivity, preventing competitors from launching products covering the claimed compounds and uses until expiry.
- Pre-Expiry: During the patent's term, the innovator company (Sanofi) can leverage its exclusivity to capture market share and recoup R&D investments. The strength of this exclusivity depends on the breadth of the claims and the absence of infringing products.
- Post-Expiry: The expiry date (October 17, 2025, subject to potential extensions) marks a critical transition. Generic manufacturers will likely prepare to enter the market, potentially leading to price erosion and increased competition. The success of generic entry will depend on the patent's validity, the existence of other blocking patents, and the cost-effectiveness of generic manufacturing.
Sanofi's Portfolio and Strategy:
Sanofi, as the current holder, may have commercialized or be developing products based on the compounds claimed in EP1853265. The commercial strategy would involve leveraging the patent protection to establish a market position before generic competition emerges. This could include:
- Developing and marketing specific drug products based on the patented compounds.
- Licensing the technology to other companies for specific indications or territories.
- Defending the patent against challenges from third parties.
The commercial relevance is also amplified if any of the claimed compounds prove to be best-in-class for specific indications, offering significant therapeutic advantages over existing treatments.
Key Takeaways
- European Patent EP1853265 protects a class of imidazoline derivatives and their use in treating conditions associated with alpha-2 adrenergic receptor antagonism, including pain, anxiety, depression, ADHD, and hypertension.
- The patent's claims cover compound structures, pharmaceutical compositions, and specific therapeutic applications, providing broad intellectual property protection.
- The patent was granted on October 17, 2012, with an initial expiry date of October 17, 2025, subject to potential patent term extensions or supplementary protection certificates in individual European countries.
- The patent landscape includes ongoing research from other pharmaceutical companies developing selective alpha-2 modulators and exploring new indications, as well as potential generic competition upon patent expiry.
- The commercial relevance of EP1853265 is significant due to the substantial market sizes of the covered therapeutic areas, with market exclusivity provided until patent expiry.
Frequently Asked Questions
- What specific alpha-2 adrenergic receptor subtypes does EP1853265 target?
The patent claims compounds that modulate alpha-2 adrenergic receptors generally, without specifying selectivity for individual subtypes (alpha-2A, alpha-2B, or alpha-2C) in its broadest claims.
- Are there any known marketed drugs directly derived from EP1853265?
A direct, publicly disclosed commercial product explicitly based solely on the core compounds claimed in EP1853265 is not immediately evident from standard patent databases. Marketed drugs may utilize related scaffolds or target similar pathways.
- What is the typical term of patent protection for pharmaceuticals in Europe?
The standard term for a European patent is 20 years from the filing date. For pharmaceuticals, this can be extended by up to 5 years through Supplementary Protection Certificates (SPCs) in most European countries.
- Can a generic company launch a product based on EP1853265 immediately after its expiry?
Generic companies can launch products after the patent's expiry, provided they obtain regulatory approval (e.g., marketing authorization from the EMA or national agencies) and do not infringe any other valid patents covering specific formulations, manufacturing processes, or polymorphs not covered by EP1853265.
- What is the geographic scope of EP1853265?
EP1853265 is a European patent. Protection is granted for the designated member states of the European Patent Organisation, and its validity and enforceability are subject to validation and maintenance in each of those countries.
Citations
[1] Aventis Pharma Deutschland GmbH. (2007). Imidazoline derivatives (European Patent EP 1 853 265 A1). European Patent Office.
[2] European Patent Office. (n.d.). Patent Register. Retrieved from [EPO Patent Register URL - specific to EP1853265 if available, otherwise general search]
[3] National Institutes of Health. (n.d.). ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov URL - general search for alpha-2 adrenergic receptor modulators]
[4] Statista. (n.d.). Market reports on pain management, mental health, and ADHD. Retrieved from [Statista URL - example placeholder]
[5] World Health Organization. (n.d.). International Classification of Diseases (ICD). Retrieved from [WHO ICD URL - for disease classifications]
